#1 of 4
88/100v3.0 six-pillar rubric
Starting at $160/mo. Defy Medical is one of the providers covered in our editorial directory that dispenses or coordinates Pentadeca Arginate (PDA).
Read review →Recovery · Next-Gen BPC
Pentadeca Arginate (PDA)
Pentadeca Arginate is a stabilized analog of BPC-157 with an arginate salt formulation, marketed as a longer-acting and more bioavailable alternative to standard BPC-157.
Pentadeca Arginate (PDA) at a glance
Pentadeca Arginate is a stabilized analog of BPC-157 with an arginate salt formulation, marketed as a longer-acting and more bioavailable alternative to standard BPC-157. Mechanism: BPC-157 analog (arginate salt). Typical route: Subcutaneous, oral. FDA status: Not FDA-approved. Dispensed by peptide compounding pharmacies. Clinical-trial evidence is limited compared with the underlying BPC-157 literature; most of the evidence base is preclinical or anecdotal
Drug classBPC-157 analog (arginate salt)
Half-lifeLonger than standard BPC-157
RouteSubcutaneous, oral
Common dosing250-500 mcg/day
FDA statusNot approved
Available throughCompounding pharmacies
Mechanism of action
PDA shares BPC-157's proposed mechanism of action: promoting angiogenesis, modulating nitric oxide pathways, and accelerating soft-tissue repair. The arginate stabilization is intended to extend half-life and improve oral and subcutaneous bioavailability.
Dosing reference
Subcutaneous: 250-500 mcg once or twice daily, typically near the injury site. Oral: 500 mcg-1 mg daily for gut-related applications. Cycles are commonly 4-6 weeks on, with re-evaluation.
Dosing information is provided for educational reference and is not medical advice. Patients should not initiate or modify any peptide regimen without consulting a licensed clinician. See our medical disclaimer.
FDA status & regulatory framework
Not FDA-approved. Dispensed by peptide compounding pharmacies. Clinical-trial evidence is limited compared with the underlying BPC-157 literature; most of the evidence base is preclinical or anecdotal.
U.S. telehealth providers that work with Pentadeca Arginate (PDA)
#2 of 4
85/100v3.0 six-pillar rubric
Starting at $180/mo. Marek Health is one of the providers covered in our editorial directory that dispenses or coordinates Pentadeca Arginate (PDA).
Read review →#3 of 4
70/100v3.0 six-pillar rubric
Starting at $110/mo. Heally is one of the providers covered in our editorial directory that dispenses or coordinates Pentadeca Arginate (PDA).
Read review →#4 of 4
71/100v3.0 six-pillar rubric
Starting at $125/mo. PeterMD is one of the providers covered in our editorial directory that dispenses or coordinates Pentadeca Arginate (PDA).
Read review →Related recovery peptides
Frequently asked questions about Pentadeca Arginate (PDA)
How is PDA different from BPC-157?
Pentadeca Arginate is the same core 15-amino-acid sequence as BPC-157 with an arginate-salt modification intended to improve stability and bioavailability. In practice, claimed advantages over BPC-157 vary between manufacturers.
Is PDA safer than BPC-157?
There is no robust head-to-head safety data. Both are not FDA-approved; safety profiles in published preclinical work are similar.